Defendant
4 cases as defendant.
Granules India Limited (NSE: GRANULES; BSE: 532482) is an Indian pharmaceutical manufacturer headquartered in Hyderabad, Telangana. Sources differ on the founding year: the company's origin dates to 1984, while its incorporation as a public limited company is cited as March 1991; it was founded by Krishna Prasad Chigurupati, who remains Chairman and Managing Director. It is publicly listed on the NSE and BSE, not a subsidiary. Market capitalization was roughly ₹21,000 crore ($2.4B) in mid-2026, with trailing-twelve-month revenue around ₹5,600 crore ($600M). Reported employee counts vary by source and date — roughly 4,000–4,300 in recent market-data filings, versus 6,166 cited in Wikipedia for March 2025.
Operations. Granules is a vertically integrated manufacturer spanning active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Its core high-volume off-patent molecules include paracetamol, ibuprofen, metformin, guaifenesin, methocarbamol, and combinations such as metformin; it also markets generic finished dosages in the US. It operates roughly ten-plus manufacturing sites, most in India plus US facilities through subsidiaries Granules Pharmaceuticals, Inc. (Chantilly, Virginia) and Granules USA. In 2025 it acquired Swiss CDMO Senn Chemicals AG (peptide development/manufacturing, via subsidiary Granules Peptides/Ascelis), extending it into peptide APIs and CDMO services. It also runs a consumer health division.
Litigation posture. Granules is an operating company and in the tracked data appears exclusively as a defendant (0 plaintiff suits, 1 defendant suit), consistent with a generic manufacturer defending brand-holder Hatch-Waxman suits rather than asserting patents. The single tracked case is in the U.S. District Court for the District of Delaware — a common ANDA venue.
Notable case. Boehringer Ingelheim Pharmaceuticals Inc. et al. v. Granules India Limited (D. Del. No. 1:25-cv-00663, filed May 29, 2025) concerned Granules' ANDA No. 220408 for 10 mg and 25 mg empagliflozin tablets, a generic of Boehringer's JARDIANCE, and asserted U.S. Patents 9,949,998; 10,258,637; 11,090,323; and 11,833,166. The case closed by consent judgment on September 2, 2025, with the patents held valid and enforceable as to that ANDA product and Granules enjoined from US marketing until expiry.
Complaint pleads infringement of US 10,736,866 arising from Granules' ANDA/Paragraph IV certification. The narrative also mentions the '062 patent, but it cannot be decoded to a full patent number from the narrative.
Most recent confirmed '306-family action. Status not confirmed.
Jazz Pharmaceuticals Ireland Ltd. sued Granules India Limited; 14 patents were asserted including the '400 patent. The case was terminated by consent judgment dismissing with prejudice on 2026-03-26.
Hatch-Waxman ANDA-style action brought by Boehringer Ingelheim entities against Granules India Limited over JENTADUETO (linagliptin/metformin HCl). The suit asserted US 9,415,016 B2 plus US 10,022,379 B2, US 11,911,388 B2, US 10,973,827 B2, and US 9,155,705 B2. It was voluntarily dismissed without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i), with plaintiffs preserving the right to re-assert.